SCHEMBL16631173

SCHEMBL16631173

C#Cc1[nH]c(=O)ccc1[C@@H]1O[C@H](CO)C(O)[C@@H]1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.38
SLC28A2 O43868 1/20 0.38
SLC29A1 Q99808 1/20 0.38
SLC28A3 Q9HAS3 1/20 0.38
CDA P32320 1/20 0.36
SLC5A2 P31639 2/20 0.34
SLC5A1 P13866 1/20 0.34
P2RY14 Q15391 2/20 0.33
P2RY2 P41231 1/20 0.33
P2RY4 P51582 1/20 0.33
P2RY6 Q15077 1/20 0.33
PYGL P06737 2/20 0.32
PYGM P11217 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GMNN O75496 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18079908 0.89 SLC28A1 (0.43) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL18079912 0.86 SLC28A3 (0.37) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631185 0.82
SCHEMBL16631572 0.82 SLC5A2 (0.37) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16631525 0.82 SLC28A1 (0.41) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631154 0.82 PYGL (0.36) CDAPYGLKDM4EGMNNLMNA
SCHEMBL16631577 0.81 SLC28A1 (0.40) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631167 0.80 SLC5A2 (0.35) CDASLC5A2SLC5A1LMNATSHR
SCHEMBL16631175 0.79 CDA (0.35) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631174 0.79 PYGL (0.35) SLC28A1SLC28A2SLC29A1SLC28A3CDA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SLC28A1 302/4885SLC28A2 214/4885SLC29A1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.